<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2238">
  <stage>Registered</stage>
  <submitdate>28/01/2009</submitdate>
  <approvaldate>28/01/2009</approvaldate>
  <nctid>NCT00831714</nctid>
  <trial_identification>
    <studytitle>Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty</studytitle>
    <scientifictitle>Xarelto in the Prophylaxis of Post Surgical Venous Thromboembolism After Elective Major Orthopedic Surgery of Hip or Knee</scientifictitle>
    <utrn />
    <trialacronym>XAMOS</trialacronym>
    <secondaryid>XA0801</secondaryid>
    <secondaryid>13802</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Venous Thromboembolism</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Rivaroxaban (Xarelto, BAY59-7939)
Treatment: drugs - Standard care treatment for VTE prophylaxis

Group 1 - 

Group 2 - 


Treatment: drugs: Rivaroxaban (Xarelto, BAY59-7939)
Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for VTE prophylaxis with Rivaroxaban has been made

Treatment: drugs: Standard care treatment for VTE prophylaxis
Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for a pharmacologic VTE prophylaxis treatment other than rivaroxaban has been made

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Data collection on: Bleeding events reported as serious or non-serious adverse events; Symptomatic thromboembolic events (DVT, PE) reported as adverse events; Uncommon adverse events (incidence rate between 0.1 % and 1 %); All cause mortality</outcome>
      <timepoint>During observation period of three months</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Female and male patients who will undergo elective hip or knee arthroplasty.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Exclusion criteria must be read in conjunction with the local product information.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>19076</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Many Locations</hospital>
    <postcode> - Many Locations</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bosnia and Herzegovina</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Cyprus</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lebanon</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Macedonia, The Former Yugoslav Republic of</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Arab Emirates</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Venezuela</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Vietnam</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bayer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Janssen Research &amp; Development, LLC</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main goal is to provide additional information to the risk-benefit assessment of the
      drug.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00831714</trialwebsite>
    <publication>Turpie AG, Haas S, Kreutz R, Mantovani LG, Pattanayak CW, Holberg G, Jamal W, Schmidt A, van Eickels M, Lassen MR. A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. Thromb Haemost. 2014 Jan;111(1):94-102. doi: 10.1160/TH13-08-0666. Epub 2013 Oct 24.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bayer Study Director</name>
      <address>Bayer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>